Copyright ©The Author(s) 2021.
World J Nephrol. May 25, 2021; 10(3): 29-36
Published online May 25, 2021. doi: 10.5527/wjn.v10.i3.29
Table 1 American College of Radiology manual classification of gadolinium-based agents relative to nephrogenic systemic fibrosis
Group I: Agents associated with the greatest number of NSF cases:
Gadodiamide (Omniscan® – GE Healthcare)
Gadopentetate dimeglumine (Magnevist® – Bayer HealthCare Pharmaceuticals)
Gadoversetamide (OptiMARK® – Guerbet)
Group II: Agents associated with few, if any, cases of NSF:
Gadobenate dimeglumine (MultiHance® – Bracco Diagnostics)
Gadobutrol (Gadavist® – Bayer HealthCare Pharmaceuticals; Gadovist in many countries)
Gadoteric acid (Dotarem® – Guerbet, Clariscan – GE Healthcare)
Gadoteridol (ProHance® – Bracco Diagnostics)
Group III: Agents for which data remains limited regarding NSF risk, but for which few, if any cases of NSF have been reported:
Gadoxetate disodium (Eovist – Bayer HealthCare Pharmaceuticals; Primovist in many countries)